Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, PD and Food Effects of SAP-001 in Healthy Subjects and Gout Patients
NCT06678581Phase 1Completed
- Sponsor
- Shanton Pharma
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sap-001 in gout and hyperuricemia (5 arms), sponsored by Shanton Pharma. Primary endpoints: Maximum Concentration at 168 hours, Area Under the Curve from time 0 to last measurable concentration at 168 hours and 5 more. Started May 2023; status: completed.
02
Drugs
sap-001
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06678581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678581.